Monoclonal antibodyFDA-approvedFirst-line
Yervoy
Generic name: ipilimumab
How it works
Blocks CTLA-4, a protein on immune cells that normally helps to prevent overactive immune responses. By blocking CTLA-4, ipilimumab allows the immune system to attack cancer cells more effectively.
Cancer types
Melanoma— All patients
Efficacy
Studies show that ipilimumab can improve overall survival in patients with advanced melanoma, with a median overall survival of approximately 11 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Nivolumab plus ipilimumab treatment shows promise for Japanese patients with lung cancer | Lung Cancer | phase-3 | Median overall survival was 41.0 months versus 15.2 months, with a 5-year overall survival rate of 38% versus 16%. | Source → |
| Testing a Special Diet with Immunotherapy in Melanoma Patients | Melanoma | phase-2 | — | Source → |
| Testing a New Vaccine and Immunotherapy Combination for Colorectal and Pancreatic Cancer | Colorectal Cancer | phase-1 | — | Source → |
| Combining Cancer Drugs May Work Better at Lower Doses | Melanoma | phase-2 | — | Source → |
| Combination Therapy Shows Promise in Advanced Melanoma | Melanoma | phase-2 | ORR was 55% in PEM200+IPI50; 61% in PEM200+IPI100. | Source → |
| Combining Immunotherapy for Melanoma After Treatment Failure | Melanoma | phase-2 | The irRECIST response rate was 29% among the entire trial population. | Source → |
| Monitoring Side Effects of Cancer Treatment with Ipilimumab | Melanoma | observational | — | Source → |
| Rare Side Effects of Cancer Treatment | Melanoma | observational | — | Source → |
| Misdiagnosing Melanoma with a Common Cancer Treatment | Melanoma | observational | — | Source → |
| Combining Cancer Drugs with Anti-Inflammatory Medications in Melanoma Patients | Melanoma | preclinical | Seven of seven evaluable patients achieved objective response, including four complete responses and three partial responses, in the certolizumab cohort. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.